Menu Back toSession 3: OPDP Research Update (Recorded)

Advertising and Promotion Regulatory Affairs Conference

This event is now offered in a new entirely virtual format.


Session 3: OPDP Research Update (Recorded)

Session Chair(s)

Kathryn J Aikin, PhD

Kathryn J Aikin, PhD

  • Senior Social Science Analyst, Research Team Lead, OPDP, CDER
  • FDA, United States
Individual FDA/OPDP researchers will present findings from OPDP research studies. Attendees will gain a better understanding of the FDA/OPDP Research program and how it may contribute to knowledge, guidance, and policy development. This session is designed to educate attendees on the regulatory research FDA has done to help inform policy and guidance development.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Understand the holistic research agenda of FDA/OPDP
  • Provide the audience with a view into individual topic areas and how they fit together
  • Identify insight into results of recent research

Speaker(s)

Kathryn J Aikin, PhD

Introduction to the OPDP Research Program

Kathryn J Aikin, PhD

  • Senior Social Science Analyst, Research Team Lead, OPDP, CDER
  • FDA, United States
Amie C O'Donoghue, PhD

Animation in Direct-to-Consumer Prescription Drug Television Advertising

Amie C O'Donoghue, PhD

  • Social Science Analyst, OPDP, CDER
  • FDA, United States
Kevin R. Betts, PhD

Physician and Consumer Capability to Detect and Inclination to Report Deceptive Prescription Drug Promotion

Kevin R. Betts, PhD

  • Social Science Analyst
  • FDA, United States
Helen W. Sullivan, PhD, MPH

Consumers’ Understanding of Oncology Clinical Endpoints: Focus Group Findings

Helen W. Sullivan, PhD, MPH

  • Social Science Analyst, OPDP, CDER
  • FDA, United States
Kathryn J Aikin, PhD

Consumers’ Experience with and Attitudes Toward Direct-to-Consumer Prescription Drug Promotion: A Nationally Representative Survey - Selected Findings

Kathryn J Aikin, PhD

  • Senior Social Science Analyst, Research Team Lead, OPDP, CDER
  • FDA, United States

Contact us